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The formationof antibodies to interferon-beta (IFN-b), a protein-based disease-modifying agent formultiple sclerosis (MS), is a problem in
clinical practice. These antibodiesmayneutralize thebiological effects of theproteindrug, potentially decreasing its therapeutic effects. By
high-resolution HLA class I and II typing we identiﬁed two HLA class II alleles associated with the development of antibodies to IFN-b. In
two independent continuous andbinary-trait association studies,HLA-DRB1*0401 andHLA-DRB1*0408 (odds ratio: 5.15)—butnot other
HLA alleles—were strongly associated with the development of binding and neutralizing antibodies to IFN-b. The associated HLA-
DRB1*04 alleles differ from nonassociated HLA-DRB1*04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding
alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1*0401 and *0408might promote binding and presen-
tationof an immunogenicpeptide,whichmayeventuallybreakTcell toleranceand facilitate antibodydevelopment to IFN-b. In summary,
we identiﬁed genetic factors determining the immunogenicity of IFN-b, a protein-based disease-modifying agent for the treatment ofMS.Introduction
Multiple sclerosis (MS [MIM 126200]) is a chronic inﬂam-
matory disease of the central nervous system. Whereas
the etiology of MS is likely to be heterogeneous, the inﬂu-
ence of genetic factors in the development of MS has been
conﬁrmed by association and linkage studies.1–4 The
crucial role of HLA alleles in the susceptibility to MS is
well established.WhereasHLA-DRB1*15 alleles are strongly
associated with MS in Europeans, DRB1*0301 and
DRB1*0401 are overrepresented inMS patients from south-
ern Europe.5,6 Overrepresentation of DRB1*04 alleles was
reported for patients from Turkey and the Canary Islands.
Although the genetic association of susceptibility to MS
with loci outside the HLA complex has been conﬁrmed in
some cases, the search for susceptibility genes continues.4
Interferon-b is the most widely used immunomodula-
tory drug for MS therapy. It is approved for treatment of
clinically isolated syndrome and relapsing-remitting MS.
Furthermore, it has antiviral activity and remains an op-
tion in the therapy of diseases such as Hepatitis-C (HCV
[MIM 609532]) or the severe acute respiratory syndrome
(SARS).7–9 Like other protein-based disease-modifying
agents, IFN-b exhibits immunogenicity.10 Even though
the technical improvement of puriﬁcation processes and
the introduction of recombinant preparations have helped
to reduce the immunogenicity of IFN-b, up to 50% of pa-
tients may develop antibodies to IFN-b (binding antibodies
[BABs]), of which a signiﬁcant proportion neutralize the
activity of IFN-b (neutralizing antibodies [NABs]) in vitroThe Amand vivo.11 Currently, three distinct recombinant prepara-
tions of IFN-b are in use for the treatment of MS. Interferon
b-1b (165 residues) is modiﬁed from naturally occurring
IFN-b by deletion of the leading methionine and a single
amino acid substitution (C17S).12 It is recombinantly
expressed in Escherichia coli (IFN-b-1b; Betaferon or
Betaseron). IFN-b-1a, recombinantly expressed in Chinese
hamster ovary cells, is identical to natural human interferon
beta (166 residues) (IFN-b-1a; Avonex, Rebif). Although
preparation and administration inﬂuence the immuno-
genic properties and the rate of antibody development,
little is known about host factors that determine immune
responses to IFN-b.13
Antibody production and generation of B cell responses
to proteins depend on the help of antigen-speciﬁc CD4þ T
cells.14 The development of antigen-speciﬁc CD4þ T cell
responses itself is strongly inﬂuenced by the individual
repertoire of HLA class II molecules, which present peptide
antigens for recognition to the T cell receptor.15,16 Given
the central role of CD4þ T cells for the development of an-
tigen-speciﬁc B cell responses, we performed high-resolu-
tion typing for HLA-A, -B, -C, -DRB1, and -DQB1 alleles
in MS patients receiving long-term IFN-b therapy.
Material and Methods
Patients
MS patients on IFN-b therapy, predominantly of northern Euro-
pean heritage, were recruited in Germany by primary-care physi-
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Table 1. Clinical Characteristics of the Initial Study and Validation Groups
Initial Study Group (n ¼ 268) Validation Group (n ¼ 242)




















Age in years [mean
(range)]
40 (17–69) 40 (19–64) 41 (17–69) 39 (16–66) 39 (21–75) 39 (21–60) 39 (21–75) 39 (16–67)
Gender (male/female) 48/88 27/58 21/30 45/87 23/54 19/40 4/14 40/124
Therapy duration in
months [mean (range)]
55 (16–147) 53 (16–147) 57 (17–112) 59 (12–156) 47 (7–127) 47 (7–111) 46 (20–127) 55 (7–146)
IFN-b1a (i.m., Avonex)-
treated (n)
6 5 1 28 4 2 2 64
IFN-b1b (s.c., Betaferon)-
treated (n)
70 37 33 48 36 24 12 50
IFN-b1a (s.c., Rebif
22 mg)-treated (n)
10 6 4 16 9 9 0 15
IFN-b1a (s.c., Rebif 44 mg)-
treated (n)




74 (26–119) 91 (35–119) 48 (26–97) 3 (9–23.5) 83 (35–140) 85 (57–140) 76 (35–96) 2 (17–24)
In vivo MXA assays,
induction (%)
[median (range)]
23 (64–135) 4 (64–50) 89 (41–135) 92.6 (12–93) 23 (45–128) 17 (45–57) 79 (53–128) 95 (70–202)
Both groups comprised a total of 510 IFN-b-treated subjects. Mean treatment duration exceeds 45 months in both cohorts. Ranges are given in brackets.
Whereas the mean age of both groups was between 39 and 41 yr, the sex ratio differed among both groups. Females were slightly overrepresented in the
validation group. Note that the number of BABs-positive subjects is higher in the IFN-b1b (Betaferon)-treated group.individuals with known anti-IFN-b1 status. The ratio of males to
females in the ﬁrst cohort was 0.53. A total of 34 patients received
IFN-b1a intramuscular injection (i.m.) once weekly (Avonex), 118
patients IFN-b1b subcutaneous injection (s.c.) every second day
(Betaferon), 26 patients 22 mg and 90 patients 44 mg IFN-b1a s.c.
three times a week (Rebif). The validation group compassed 242
patients with a male-female ratio of 0.36. Avonex treatment was
administered to 68 patients, and Rebif was given to 88 individuals
and 86 patients received Betaferon. As expected, IFN-b1a i.m.
(Avonex)-treated patients were underrepresented in the study as
a result of the lower frequency of antibody development in this
group compared to patients treated with the formulations for
s.c. application. Mean age was 39.8 yr in the ﬁrst and 39.0 yr
in the second group (Table 1). Average treatment duration was
57 months in the ﬁrst and 52 months in the second group. The
duration of the drug exposure did not differ signiﬁcantly among
treatment groups. All patients gave their written informed con-
sent. The study was approved by the ethics committees of the
Universities of Du¨sseldorf and Munich.
HLA Genotyping
For the ﬁrst study cohort, HLA genotyping forHLA-A, -B, -C,DRB1,
and DQB1 was performed by hybridization of sequence-speciﬁc
oligonucleotide probes immobilized on microspheres with ampli-
ﬁed genomic DNA samples followed by ﬂow ﬂuorescence-inten-
sity analysis according to the instructions of the manufacturer
(One Lambda, Canoga Park, CA, USA). In the validation study
cohort, the HLA analysis was restricted to HLA-DRB1*04 only.
The presence or absence of HLA-DRB1*04 was determined by se-
quence-speciﬁc primer polymerase chain reaction (PCR-SSP) using
a nested approach as previously described.17 In both study co-
horts, the identiﬁcation ofHLA-DRB1*04 alleles was accomplished220 The American Journal of Human Genetics 83, 219–227, Augustby group-speciﬁc sequencing of exon 2 of HLA-DRB1*04-positive
samples according to the manufacturer’s instruction (Protrans,
Ketschau, Germany).
Assays for Binding and Neutralizing Antibodies
To detect antibodies against IFN-b, we performed a standardized
capture ELISA as described.18 Deﬁned positive and negative serum
samples were included in each assay to obtain a standard curve for
comparison of different assays. The standard curve ranged from
100% (highest positive control) to 0% (no antibodies). Serum pos-
itivity of all tested samples was normalized on the basis of these
standard curves. Reactivity above 25% of the highest positive
control was considered to be antibody positive (the cut-off value
corresponded to the median of 50 control donors þ ﬁve standard
deviations). The biological in vivo activity of IFN-b was measured
by MX1 (MxA) gene expression with TaqMan real-time PCR.19
Twelve hours after IFN-b injection, blood samples were drawn
from subjects and mRNA was isolated according to the manufac-
turer’s instructions. TaqMan reverse-transcription reagents (Ap-
plied Biosystems, Foster City, USA) were used to convert mRNA
to cDNA. cDNA levels were detected with ABI’s GeneAmp via
the protocols described. The housekeeping gene GAPDH was
used as internal control. Normalization was done according to
the DDCt-method. In each assay, the same positive and negative
samples were included to ensure the quality of the assay. Anti-
bodies were considered biologically active when the MX1 (MxA)
induction was decreased by more than 50% compared to newly
treated antibody-negative control donors.
In 203 patients from the ﬁrst patient group, an MX1 RNA NAB
assaywas also performed to determine the in vitro neutralizing an-
tibody activity. A human lung carcinoma cell line (A549, Ameri-
can Type Culture Collection, #CLL-185) was diluted in culture8, 2008
medium (2% BCS, 2 mM L-glutamine, 50 U/ml penicillin G, and
0.05 mg/ml streptomycin sulfate in alpha-MEM) at a concentra-
tion of 105 cells/ml, and each well of a microtiter plate was incu-
bated overnight with 50 ml of this solution. Screening samples
are diluted 1:10 and incubated with Betaferon 25 IU/ml for 45
min at 37C and 5% CO2 on a microtiter plate. These samples
are then transferred to the plate containing the A549 cells and
incubated for 6.5 hr. For the standard curve, Betaferon with con-
centrations from 0 to10 IU was used. After that, the supernatant
was decanted and cells were lysed with a lysis buffer.
A DCt value of a sample of less than 50% of the highest concen-
tration on the standard curve was considered NAB negative. Oth-
erwise, the sample was titrated. Titration samples were diluted se-
rially beginning at 1:20 up to 1:10,240, and each dilution was
incubated with Betaferon 25 IU/ml for 45 min at 37C and 5%
CO2with an extra microtiter plate. These samples were then trans-
ferred to the plate containing the A549 cells and incubated for 6.5 hr.
The supertnatant was decanted and cells were lysed with a lysis
buffer followed by RNA extraction and transcription as described
below. MX1 RNA was isolated semiautomatically with 6100 ABI
PRISM Nucleic Prep Station. Lysates were ﬁltered through a mem-
brane to capture RNA. After several washing steps with washing
buffers (by Applied Biosystems), RNA was eluted by addition of
a puriﬁcation elution solution into an extraction plate and stored
at 80C. After Master Mix was prepared (high-capacity cDNA Kit
by Applied Biosystems) and applied to a new microtiter plate, the
samples from the above RNA plate were thawed and transferred.
RNA was transcribed into cDNA according to the manufacturer’s
instructions. Endogenous control (housekeeping gene) and tar-
get-detecting primers were mixed with the appropriate Master
Mix (Applied Biosystems), and c-DNA was added. A predeﬁned
program (Applied Biosystems) for MX1 and house keeping gene
(eukaryotic 18 s rRNA) detection was applied. A threshold is set
in the exponential phase of rtPCR and the difference between
the MX1 threshold cycles and the housekeeping gene cycles was
determined (¼ DCt).
Computational Biology and Statistics
In order to attenuate the problem of deliberately setting up thresh-
olds for ELISA and MX1 values to declare cases and controls, a
binary-trait case-control association study was supported by con-
tinuous trait analysis for single HLA alleles and haplotypes. This
bilateral approach was used for the initial study group as well as
for the validation group. For identiﬁcation of genetic variation
of anti-IFN-b formation, the continuous normalized antibody
reactivities were directly compared among carriers of different
alleles. In the binary-trait case-control study, patients were consid-
ered antibody positive (cases) if the anti-IFN-b levels exceeded the
25% cutoff value. Otherwise, patients were considered antibody
negative (controls). Additionally, antibody-positive patients were
considered NABs positive if theirMX1mRNAs were reduced below
50% of MX1 levels of newly treated patients. The remaining anti-
body-positive patients who had not signiﬁcantly reduced MX1
mRNA levels were considered BABs positive. For the testing of
differences of location parameters for MX1 gene expression and
anti-IFN-b levels, the two-sided nonparametric Wilcoxon test
was applied. p values were adjusted for multiple testing with the
false-discovery rate (FDR). For identiﬁcation of haplotype-speciﬁc
associations with continuous (MX1 and anti-IFN-b levels) and
binomial trait types (NABS, BABs, and control subgroups), the ge-
netic analysis package (gap) of the R Project for statistical comput-
ing was applied with score tests for association as describedThe Ameby 20,21. Haplotype-speciﬁc scores have been calculated with a score











where yi denotes the measured trait, ~yi a mean trait value, and aðfÞ
a measure of variation. EpðXgiÞ denotes expectation value over the
posterior distribution of the null hypothesis. The score statistics
provide a measure for the covariation of a haplotype and the ex-
amined trait.21 However, this analysis has explorative character,
because the results are based on the maximization of probabilities
rather than a known linkage phase.
Multiple sequence alignments were generated with the CLUS-
TALW application. The sequences of HLA alleles were obtained
from the HLA repository at the European Bioinformatics Institute
(EBI). Linkage disequilibrium (LD) tests for HLA alleles as well as
multilocus analysis for LD were done with the PyPop package.
Results
HLAClass II but Not HLA Class I Alleles Are Associated
with Antibody Occurrence
Two hundred and sixty-eight MS patients on long-term
IFN-b therapy were included in the ﬁrst group of the study.
One hundred and thirty-six patients of the study group
had developed antibodies to IFN-b (determined by cELISA),
of whom 85 developed neutralizing antibodies as deter-
mined by the in vivo induction of the IFN-b response
gene MX1. One hundred and thirty-two patients were an-
tibody negative (Table 1). In the second group, 76 patients
were antibody positive, including 59 with neutralizing
in vivo activity. The remaining 164 individuals were anti-
body negative. For analysis of possible confounding effects,
treatment-independent allele distribution was tested. The
null hypothesis of independency holds in the study (chi-
square ¼ 55.34, p value ¼ 0.65) as well as in the validation
group (chi-square ¼ 8.333, p value ¼ 0.97).
All patients from the initial study group were typed for
HLA class I and II alleles. Although we expected an associ-
ation of HLA class II genes with antibody development, we
also typed class I genes as internal negative control. As ex-
pected, only small differences between antibody-negative
and -positive patients were found for HLA class I alleles.
Median anti-IFN-b levels were lower in HLA-C*16 carriers
(p value ¼ 0.007, FDR ¼ 0.095) and higher in HLA-C*2
and HLA-B*57 (p value ¼ 0.03, FDR % 0.1) carriers,
although the associations did not reach signiﬁcance after
adjustment for multiple testing.
By contrast, signiﬁcant differences were observed for the
HLA class II alleles. The largest difference of median anti-
IFN-b levels was observed between DRB1*04-positive (n ¼
58) and DRB1*04-negative subjects (n ¼ 210) (p ¼ 0.006).
DRB1*04-positive patients showed signiﬁcantly higher
anti-IFN-b levels with a median normalized antibody
titer of 55.1% compared to DRB1*04-negative patients
(median ¼ 17.1%) (Table 2). Signiﬁcantly reduced median
anti-IFN-b reactivities were also found for DRB1*1101rican Journal of Human Genetics 83, 219–227, August 8, 2008 221
(pvalue¼0.013)andDRB1*1104 (pvalue¼0.02).However,
null hypothesis was kept after the FDR procedure. Likewise,
elevated anti-IFN-b reactivities in DRB1*1601-positive pa-
tients (p value¼ 0.02) were not signiﬁcant after correction.
HLA-DRB1*04 Alleles Confer a Higher Risk
of Developing Antibodies during IFN-b Therapy
A majority of DRB1*04-positive patients included in the
initial study group carried the DRB1*0401 allele (n ¼ 42),
whereas only 12 subjects were DRB1*0404-positive. Only
four patients carried DRB1*0408 (Table 3). Differences of
location parameters for DRB1*0401 (FDR ¼ 0.012) and
DRB1*0408 (FDR ¼ 0.048) were signiﬁcant after correction
for multiple testing. On the other hand, average cELISA
levels for DRB1*0404 were lower compared to DRB1*04-
negative patients. After FDR correction, null hypothesis
was kept for DRB1*0404 despite a signiﬁcant single test
(p value ¼ 0.031, FDR ¼ 0.16).
To further investigate the role of DR4 alleles for antibody
development, we determined the activity of IFN-b anti-
bodies by another assay, which was used in a number of
clinical studies. The in vitro MX1 test was performed on
Table 2. Anti-IFN-b Levels and Low-Resolution HLA Class II
Typing in the Study Group
Allele Carriersa Anti-IFN Reactivity (%)b Statistics
Specificity n Median Range pc FDRd
DR 1 31 14.6 0.7–100.5 0.2 0.43
DR 3 48 17.9 3.2–110.8 0.34 0.55
DR 4 58 55.9 3.2–119.3 0.004 0.025
DR 7 50 18.2 9.2–119.3 0.41 0.59
DR 8 16 37 0.2–103.5 0.87 0.87
DR 10 5 6.7 1.8–43.4 0.14 0.43
DR 11 40 6.3 4.5–112.1 0.003 0.02
DR 12 7 46.6 4.7–78.0 0.69 0.75
DR 13 53 17.5 9.22–110.8 0.2 0.43
DR 14 4 41.8 9.92–91.2 0.55 0.65
DR 15 155 28.3 4.6–112.1 0.26 0.48
DR 16 21 90.8 0.0–103.0 0.006 0.03
DQ 2 90 17.7 9.2–110.8 0.1 0.5
DQ 3 121 33.7 4.7–119.3 0.99 0.99
DQ 4 15 54.4 0.3–103.5 0.46 0.74
DQ 5 60 18.3 9.2–102.9 0.59 0.74
DQ 6 180 28.3 4.6–112.1 0.28 0.7
The anti-IFN-b levels are compared among different HLA class II alleles.
Median anti-IFN-b levels are significantly elevated in patients carrying
the DR4 and DR16 alleles (in bold). Subjects carrying the DR11 serotype
show a significant decrease of anti-IFN-b, indicating a protective effect
of DR11 alleles (in bold). Significant results for HLA-DQ serotypes were
not observed.
a For all alleles listed, note that heterozygous allele carriers occur twice,
and homozygotic allele carriers occur only once. Only alleles that occurred
more than twice are shown.
b Anti-IFN reactivity was determined as described in the Material and
Methods. Values above 25% identified patients with anti-IFN antibodies.
c p value was determined by comparison of the anti-IFN level of allele
carriers to that of all nonallele carriers.
d p values have been adjusted to multiple testing by using the false-
discovery rate method (FDR). Adjusted p values below 0.05 were considered
to be statistically significant (in bold).222 The American Journal of Human Genetics 83, 219–227, August203 randomly selected samples. As expected, a signiﬁcant
increase (p value ¼ 0.003) of neutralizing in vitro activity
was found in sera of HLA-DRB1*0401- and *0408-positive
subjects (median activity ¼ 8462 NU) compared to sera
from HLA-DRB1*0401- and *0408-negative patients (me-
dian activity ¼ 0) (data not shown).
For validation of our initial ﬁndings, we used a second
study cohort and analyzed the most signiﬁcant results for
DRB1*04. HLA genotyping of the validation group sup-
ported the previous ﬁndings. Fifty-nine of 242 individuals
wereDRB1*04 positive.DRB1*0401 carriers showed signiﬁ-
cantlyhigher levels of anti-IFN-b antibodies.Median cELISA
positivitywas 71.8% (p value¼ 0.005, FDR¼ 0.03) (Table 3).
Five subjects carried the DRB1*0408 allele, with a median
level of 91.6%. Whereas the elevation of ELISA reactivity
was signiﬁcant in a single test, null hypothesiswas kept after
correction formultiple testing (p value¼ 0.04, FDR¼ 0.15).
In a combined analysis of anti-IFN-b levels for DR4-pos-
itive and DR4-negative carriers of validation and study
groups, a highly signiﬁcant elevation of anti-IFN-b levels
was found in carriers of DR4 alleles (median reactivity ¼
55.1%, p value % 0.01) (Figure 1). Fifty-four of 74 HLA-
DRB1*0401 carriers showed antibodies during IFN-b treat-
ment. In DRB1*0401- and *0408-negative subjects, 153 of
429 showed seroconversion, resulting in an odds ratio of
4.9 for HLA-DRB1*0401-positive carriers. The odds ratio
for DRB1*0408 was 14.4, with four of ﬁve allele carriers
being antibody positive. A highly signiﬁcant increase of
ELISA reactivities was observed in a comparison of all
HLA-DRB1*0401- and 0408-positive carriers versus
HLA-DRB1*0401- and *0408-negative carriers (Figure 2)
(p value % 0.01). Furthermore, the difference of anti-IFN-
b levels among DRB1*0401 (median reactivity ¼ 70.6%)
and DRB1*0408 (median reactivity ¼ 96.4%) is signiﬁcant
(p value¼ 0.006). Because of the small number of homozy-
gous DRB1*04 carriers, a comparison with DRB1*04-nega-
tive or heterozygous carriers was not possible.
The haplotype analysis was performed with score statis-
tics for ambiguous haplotypes. DRB*11 alleles might have
a protective inﬂuence: DRB1-DQB1 haplotype analysis
shows a signiﬁcant reduction of anti-IFN-b levels in
DRB1*1101-DQB1*0301 and DRB*1104-DQB1*0301 car-
riers. ElevatedMX1mRNA levels in carriers of these haplo-
types support this observation. A signiﬁcant increase of
anti-IFN-b reactivity could be observed for DRB1*0401-
DQB1*0301 and DRB1*0401-DQB1*0302 haplotypes. The
reduction of MX1 mRNA levels, however, was not signiﬁ-
cant (p value R 0.5). Reduced MX1 levels as well as in-
creased antibody reactivities were signiﬁcantly changed
in patients carrying the DRB1*0408-DQB1*0301 haplo-
type. Susceptibility to seroconversion was increased for
DRB1*1601-DQB1*0502 carriers. The DRB1*1601-
DQB1*0502-positive carriers also showed signiﬁcantly
decreased MX1 levels (Table 4).
As expected pairwise linkage disequilibrium was signiﬁ-
cant for all observed major histocompatibility complex
(MHC) loci (p value % 0.001). Strongest disequilibria8, 2008
Table 3. Anti-IFN-b Levels for Alleles of the HLA-DRB1 Locus in the Study and Validation Groups
Allele Carriersa,b Anti-IFN Reactivity (%)c Statistics
DRB1 n Median Range pd FDRe
Inital Study Group
0101 27 10.8 0.83–100.5 0.12 0.45
0301 48 17.8 3.16–110.8 0.34 0.66
0401 42 66.6 3.18–119.3 4e-04 0.012
0404 12 6.6 1.75–96.54 0.031 0.16
0408 4 98.5 90.5–109.8 0.003 0.048
0701 50 18.2 9.2–119.3 0.41 0.66
0801 15 39.4 0.2–109.5 0.74 0.8
1001 5 6.7 1.79–43.4 0.14 0.47
1101 32 27.0 4.6–112.1 0.013 0.13
1104 8 3.1 0.6–48.62 0.02 0.14
1201 7 46.6 4.8–78.0 0.69 0.8
1301 25 38.1 2.1–102.9 0.74 0.8
1302 18 15.8 9.2–110.8 0.35 0.66
1303 12 11.9 1.61–81.7 0.24 0.6
1501 153 30.5 4.6–112.1 0.43 0.66
1502 3 87.3 3.4–103.2 0.31 0.66
1601 17 90.8 0.1–102.9 0.02 0.13
1602 3 77.6 3.9–95.29 0.44 0.66
Validation Group
DR4 183 5.5 17.3–140.3 0.12 0.21
DR4þ 59 10.1 8.3–123.1 0.12 0.21
0401 31 71.8 5.4–120.4 0.005 0.03
0402 6 0.3 7.0–23.17 0.01 0.21
0403 6 3.4 8.3–89.6 0.37 0.43
0404 9 1.9 5.9–84.1 0.22 0.31
0407 2 47.8 2.8–92.8 0.51 0.51
0408 5 91.6 3.7–123.1 0.04 0.15
A significant elevation of IFN-b reactivity is seen for DRB1*0401 and DRB1*0408 (in bold) after adjustment for multiple testing. Only alleles that occurred
more than twice are shown. In contrast to the findings in the low-resolution analysis, a significant increase of anti-IFN-b levels in DRB1*1601-positive
subjects vanishes after the FDR procedure. Likewise, the potential protective effect of DRB1*0404 does not pass the significance criterion after adjustment
for multiple testing. In the validation group, a significant elevation of IFN-b reactivity is seen in single tests for DRB*0401 (in bold) as well as for
DRB1*0408. Because of an insufficient number of cases, however, significance vanishes after correction for multiple tests for DRB1*0408. Because of
the small number of cases, a potential protective effect of DRB1*0402 did not pass the FDR significance criterion. The results in the validation group
support our previous findings.
a For all alleles listed, note that heterozygous allele carriers occur twice, and homozygotic allele carriers occur only once. Only alleles that occurred more
than twice are shown.
b Heterozygous allele carriers (*0401þ and *0408þ) occur twice.
c Anti-IFN reactivity was determined as described in the Material and Methods. Values above 25% identified patients with anti-IFN antibodies.
d p value was determined by comparison of the anti-IFN level of allele carriers to that of all nonallele carriers.
e p values have been adjusted to multiple testing by using the false-discovery rate method (FDR). Adjusted p values below 0.05 were considered to be
statistically significant (in bold).were found for HLA-DRB1:DQB1 (D’ ¼ 0.94), HLA-B:C
(D’ ¼ 0.92), and HLA-B:DRB1 (D’ ¼ 0.68). Haplotype fre-
quencies for HLA class I alleles with signiﬁcant increases
of anti-IFN-b reactivities in single test (Table S1 available
online) do not indicate a common transmission with
DRB1*0401 and DRB1*0408 (data not shown).
HLA-DRB1*04 Promotes the Development of Binding
and Neutralizing Antibodies Independent
of the IFN-b Formulation
WhereasDRB1*0401 andDRB1*0408 are signiﬁcantly asso-
ciated with the presence of antibodies, HLA-DRB1*0401
and *0408 frequencies were not different between patients
whodevelopedNABs or BABs (p value> 0.05) (Table 5), sug-The Amegesting that the antibody development itself but not their
neutralizing capacity is inﬂuenced by the HLA alleles. The
rejection of the alternative hypothesis might, however, be
caused by an insufﬁcient power of the test.
The odds ratios in the study and validation group for the
development of antibodies to IFN-b were 5.15 for HLA-
DRB1*0401-positive patients and 9.6 for HLA-DRB1*0408-
positive patients. Odds ratios were increased for all IFN-b
preparations, although they did not reach signiﬁcance in
the IFN-ba i.m.-treated and IFN-ba 22 mg s.c.-treated
patients as a result of the low numbers of patients in these
treatment groups (odds ratios were 3.2 and 8, respectively).
The strongest effect was observed in patients who received
IFN-b1b s.c. treatment (Table 5).rican Journal of Human Genetics 83, 219–227, August 8, 2008 223
HLA Alleles Associated with Antibody Development
Share a Similar Peptide-Binding Motif
To further investigate themolecular basis for HLA class II-re-
stricted antibody development, we compared the sequences
of the antibody-associated DRB1*0401 and DRB1*0408 to
the DRB1*0402, DRB1*0403, and DRB1*0404 alleles that
are not associated with antibody development. DRB1*0401
and DRB1*0408 differ by one amino acid (71 K/R).
DRB1*0401 and DRB1*0408 differ from DRB1*0404,
DRB1*0402, and DRB1*0403 at position 86, which forms
the ﬁrst pocket of the peptide-binding groove located at
the terminal end of the same alpha-helix (Figure 3). Both
alleles associatedwithantibodydevelopment share aglycine
at position 86, whereas the nonassociated alleles have a
valine at this position (86 G/V).
Discussion
As of December, 2006, 65 new biopharmaceuticals had
been approved in the U.S., European Union, and Japan
since 1999. Like IFN-b, 47 of these new biopharmaceuticals
are derived from recombinant DNA technology.22 Applica-
tions range from the treatment of more prevalent rheu-
matic diseases (Ethanercept) to rare acquired or inherited
disease with protein deﬁciencies (Galsulfase). It is pre-
dicted that many more therapeutic proteins will become
available in the near future for an even wider range of
indications.10 Despite their therapeutic potential, immu-
nogenicity is a common problem to most, if not all, pro-
tein-based biopharmaceuticals and an important aspect
of their safety. Antibodies might not only lead to the loss
of drug efﬁcacy but may also induce severe allergic reac-
tions or neutralize the activity of endogenously produced
protein.23 It has been argued that in the absence of resil-
ient predictors of immunogenicity, patients might be put
at a high risk.24 Preparation, handling, packaging, dose,
frequency, and route of administration and treatment du-
ration seem to affect immunogenicity of biopharmaceuti-
cals.25–27 However, the role of genetic factors in
Figure 1. Comparison of Anti-IFN-b Reactivities for HLA-DR
Serological Equivalents in the Study Group
Median ELISA optical density (OD) of heterozygous DR4 carriers
was significantly elevated compared to DR4-negative individuals
(p value% 0.01).
Figure 2. Comparison of Anti-IFN-b
Reactivities for HLA-DRB1 Alleles in the
Study and Validation Groups
A significant increase of ELISA reactivities
was measured for HLA-DRB1*0401 and
HLA-DRB1*0408 alleles (p value % 0.01).
DRB1*0402, DRB1*0403, and DRB1*0404
seem to have a protective effect.
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immunogenicity to protein-based therapeutics has not
been addressed. In the present study we show that—be-
sides the inﬂuence of different preparations on immunoge-
nicity—genetic factors play an important role in the devel-
opment of antibodies against protein therapeutics.
Patients who carry the HLA-DRB1*0401 or HLA-
DRB1*0408 allele show a 5- and 14-fold increased risk to
develop antibodies to IFN-b, respectively. This results in
an average relative risk of 2.07 for DRB*0401- and






DRB1 DQB1 Freq Score p Score p
0101 0501 0.05 1.3 0.2 1.93 0.05
0301 0201 0.10 0.2 0.8 0.68 0.5
0401 0301 0.02 0.7 0.5 2.05 0.04
0401 0302 0.06 1.4 0.2 3.35 8e-04
0404 0302 0.02 0.9 0.4 2.13 0.03
0408 0301 0.01 2.6 0.01 2.76 0.006
0701 0201 0.09 0.2 0.8 0.7 0.5
0701 0303 0.01 0.2 0.8 0.63 0.5
0801 0402 0.03 0.8 0.4 0.25 0.8
1001 0501 0.01 1.1 0.3 1.61 0.1
1101 0301 0.06 2.8 0.004 2.16 0.03
1104 0301 0.02 2.1 0.04 2.23 0.03
1201 0301 0.01 0.1 0.9 0.49 0.6
1301 0603 0.04 0.7 0.5 0.15 0.9
1302 0604 0.02 0.6 0.5 0.44 0.7
1302 0609 0.01 2.1 0.03 1.68 0.09
1303 0301 0.02 1.4 0.2 1.58 0.1
1501 0602 0.30 0.5 0.7 0.54 0.6
1501 0603 0.02 0.5 0.6 0.13 0.9
1501 06XX 0.01 0.4 0.7 1.14 0.3
1502 0601 0.01 0.9 0.4 1.16 0.2
1601 0502 0.03 2.7 0.006 2.77 0.006
1602 0502 0.01 1.1 0.3 0.9 0.4
A significant increase of anti-IFN-b activities can be observed for haplo-
types containing HLA-DRB1*0401, DRB1*0408 and DRB1*1601 alleles,
HLA-DRB1*11 and DRB1*0404 alleles have a protective effect on serocon-
version (in bold). Additionally, for DRB1*1601 and DRB1*0408 a significant
reduction of MX1 levels is seen. Interestingly, even though not significant
in single allele tests, the haplotype DRB1*1601-DQB1*0502 shows a signif-
icant reduction of MX1 levels and elevation of anti-IFN-b levels. Scores
reflect the strength and the direction of the effects. The % reactivity of
each sample is related to the highest measured OD of positive controls
(MS patients with high titers of anti-IFN-b).DRB*0408-positive patients. Although the HLA-
DRB1*0401 or HLA-DRB1*0408 alleles increase the risk of
developing antibodies in response to all IFN-b formula-
tions, it remains to be determined, in further studies and
with a different study design, whether formulations with
higher immunogenicity are more affected by the HLA hap-
lotype than those with low immunogenicity.
Table 5. Odds Ratios for HLADR*0401- and HLADR*0408-
Positive Allele Carriers













BABs 23 46 0.7 (> 0.05)
ABs 60 153
no ABs 21 276 5.2(< 0.0001)
IFN-b1a (i.m., Avonex)
ABs 3 7
no ABs 11 81 3.2 (> 0.1)
IFN-b1b (s.c., Betaferon)
ABs 36 70
no ABs 5 93 9.6 (< 0.0001)
IFN-b1a (s.c., Rebif 22 mg)
ABs 4 15
no ABs 1 30 8 (0.06)
IFN-b1a (s.c., Rebif 44 mg)
ABs 17 61
no ABs 4 72 5 (< 0.005)
The difference of NABs and BABs cases among DRB1*0401- and DRB1*0408-
positive patients was not significant in chi-square tests for the study (p ¼
0.19) as well as the validation group (p ¼ 0.50). Odds ratios for the devel-
opment of antibodies are increased irrespective of the type of the IFN-b
preparation. This observation is true for the study as well as for the
validation group. Overall, the relative risk (RR) for DRB1*0401- and
DRB1*0408-positive carriers was 1.85 in the study and 2.43 in the valida-
tion group. Because of missing observations (no antibody-negative
patients with HLA-DRB1*0401 or HLA-DRB1*0408) in the validation group,
the exact odds ratio could not be calculated for IFN-b1a (s.c., Rebif 22 mg).Figure 3. Multiple Sequence Alignment
of DR4 Alleles
HLA-DRB1*0401 and DRB1*0408 only differ
in position 71 (site A). In contrast to pro-
tecting DR4 alleles, both sequences encode
for a glycine in position 86 (site B). The
residue is part of the C-terminal end of
the epitope-binding alpha helix of the
MHCII complex. The substitution of a large
with a small hydrophobic amino acid at
this position potentially increases the
immunogenicity of IFN-b.
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These results are in line with the central role of T cells in
eliciting B cell responses to protein targets: It seems that
the peptide-binding motif of both alleles allows processing
and binding of an IFN-b peptide that breaks tolerance by
promoting a strong T helper cell response to the IFN-b
protein. This breakdown of tolerance promotes a B cell
response that eventually leads to the development of an
antibody production against the IFN-b protein. It is strik-
ing that this effect critically depends on a single amino
acid in the HLA-DRB1*04 allele sequence. The 86 G/V
substitution in HLA-DRB1*04 alleles is likely to interfere
with elevated immunogenicity either by altering the bind-
ing afﬁnity of the IFN-b peptide because of secondary
structure changes of the epitope-binding alpha helix or
by affecting the presentation of the IFN-b peptide itself.
It seems that these two alleles inﬂuence the general likeli-
hood of developing an antibody response independent
of the IFN-b preparation. Although antibody development
was strongly affected by the alleles, the neutralizing activ-
ity of the antibodies was not signiﬁcantly inﬂuenced by
these HLA alleles. This suggests that bothHLA-DRB1*04 al-
leles increase the likelihood of breaking tolerance to the
protein by antibody production. Other factors, however,
might determine whether the antibodies will neutralize
IFN-b. One of those factors could be the intensity of an
immune response to IFN-b. However, the rejection of the
alternative hypothesis that the development of neutraliz-
ing antibodies is determined by HLA-DRB1*04 alleles
might be due to insufﬁcient test power and remains to be
clariﬁed in further studies.
Interestingly, HLA-DRB1*0401 has been associated with
the development of autoantibodies against insulin. Congia
et al. identiﬁed an immunodominant epitope in
DRB1*0401 transgenic mice that would have been proteo-
lytically destroyed under normal conditions. Additionally,
this epitope was processed and presented by human
DRB1*0401-positive Epstein-Barr virus-transformed B
cells.28 First reports on the inﬂuence of HLA-DR4 serotypes
in the development of porcine insulin antibodies date back
to the early 1980s.29 The smaller glycinemight endorse the
binding of epitopes that contain larger amino acids in the
vicinity of the substitution site or promote binding by
a slight modiﬁcation of the secondary structure. Although
HLA-DRB1*0101 is similar to HLA-DRB1*0401 (both carry
a glycine at position 86) and has analogous disease-modify-
ing properties inMS, onlyHLA-DRB1*0401 inﬂuences anti-
body development to IFN-b.30,31 Although not signiﬁcant
in single-allele tests, the explorative haplotype analysis
based on a score test for unkown linkage phase reveals a
signiﬁcant reduction of MX1 production in DRB1*0408-
DQB1*0301 carriers. Additionally, haplotype analysis
showed a signiﬁcant increase of anti-IFN-b reactivity and re-
duced MX1 mRNA expression in DRB1*1601-DQB1*0502
carriers, pointing to alleles other than DRB1*0401 and
DRB1*0408 thatmight be associatedwith the development
of binding and neutralizing antibodies. This is especially
true for HLA-DRB1*16 alleles that also potentially increase226 The American Journal of Human Genetics 83, 219–227, Augustthe risk to develop antibodies against IFN-b. On the other
hand, DRB1*1101 alleles seem to have a protective effect
with respect to antibody production. It has been recently
shown that trans interactionsofHLA-DRB1 alleles play a sig-
niﬁcant role in the susceptibility to MS.32,33 Such trans in-
teractions might also play a role in the immunogenicity of
biotherapeutics. Hence, this study suggests that further ge-
netic studies should be undertaken to clarify the inﬂuence
of hereditary factors in immunogenicity of biotherapeutics
and improve treatment decisions.
Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.ajhg.org/.
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